Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/216321
Title: Continuous and differential improvement in worldwide access to hematopoietic cell transplantation: activity has doubled in a decade with a notable increase in unrelated and non-identical related donors
Author: Atsuta, Yoshiko
Baldomero, Helen
Neumann, Daniel
Sureda, Anna
Devos, Jakob D.
Iida, Minako
Karduss, Amado
Purtill, Duncan
Elhaddad, Alaa M.
Bazuaye, Nosa G.
Bonfim, Carmem
De La Camara, Rafael
Chaudhri, Naeem A.
Ciceri, Fabio
Correa, Cinthya
Frutos, Cristobal
Galeano, Sebastian
Garderet, Laurent
Gonzalez Ramella, Oscar
Greco, Raffaella
Hamad, Nada
Hazenberg, Mette D.
Horowitz, Mary M.
Kalwak, Krzysztof
Ko, Bor-Sheng
Kodera, Yoshihisa
Koh, Mickey B.C.
Liu, Kaiyan
McLornan, Donal P.
Moon, Joon Ho
Neven, Benedicte
Okamoto, Shinichiro
Pasquini, Marcelo C.
Passweg, Jakob R.
Paulson, Kristjan
Rondelli, Damiano
Ruggeri, Annalisa
Seber, Adriana
Snowden, John A.
Srivastava, Alok
Szer, Jeff
Weisdorf, Daniel
Worel, Nina
Greinix, Hildegard
Saber, Wael
Aljurf, Mahmoud
Niederwieser, Dietger
Keywords: Hematopoesi
Malalties hematològiques
Hematopoiesis
Hematologic diseases
Issue Date: 9-May-2024
Publisher: Ferrata Storti Foundation (Haematologica)
Abstract: Promoting access to and excellence in hematopoietic cell transplantation (HCT) by collecting and disseminating data on global HCT activities is one of the principal activities of the Worldwide Network for Blood and Marrow Transplantation, a non-governmental organization in working relations with the World Health Organization. HCT activities are recorded annually by member societies, national registries and individual centers including indication, donor type (allogeneic/autologous), donor match and stem cell source (bone marrow/peripheral blood stem cells/cord blood). In 2018, 1,768 HCT teams in 89 countries (6 World Health Organization regions) reported 93,105 (48,680 autologous and 44,425 allogeneic) HCT. Major indications were plasma cell disorders and lymphoma for autologous, and acute leukemias and MDS/MPN for allogeneic HCT. HCT numbers increased from 48,709 in 2007. Notable increases were seen for autoimmune diseases in autologous and hemoglobinopathies in allogeneic HCT. The number of allogeneic HCT more than doubled with significant changes in donor match. While HCT from HLA-identical siblings has seen only limited growth, HCT from non-identical related donors showed significant increase worldwide. Strongest correlation between economic growth indicator of gross national income/capita and HCT activity/10 million population was observed for autologous HCT (correlation coefficient [r]=0.79). HCT from unrelated donors showed strong correlation (r=0.68), but only moderate correlation was detected from related donors (r=0.48 for HLA-identical sibling; r=0.45 for other). The use of HCT doubled in about a decade worldwide at different speed and with significant changes regarding donor match as a sign of improved access to HCT worldwide. Although narrowing, significant gaps remain between developing and non-developing countries.
Note: Reproducció del document publicat a: https://doi.org/10.3324/haematol.2024.285002
It is part of: Haematologica, 2024, vol. 109, num. 10, p. 3282-3294
URI: https://hdl.handle.net/2445/216321
Related resource: https://doi.org/10.3324/haematol.2024.285002
ISSN: 1592-8721
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
11584-Article Text-84308-2-10-20240925 (1).pdf2.67 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons